NeuroSense Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of February 2024 for NeuroSense Therapeutics Ltd., a foreign private issuer headquartered in Herzliya, Israel. The report was filed on February 7, 2024, to disclose a material corporate event regarding the company's stock listing status.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a regulatory compliance event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is that NeuroSense Therapeutics Ltd. has regained compliance with the NASDAQ Minimum Bid Price Rule. This status was confirmed via a press release issued on February 7, 2024, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the context of the listing compliance. The document serves primarily to incorporate the press release by reference into the company's Registration Statements on Form S-8 and Form F-3.
Key Facts for Investor Verification
- Verify the current trading price of NeuroSense Therapeutics Ltd. to confirm sustained compliance with the NASDAQ Minimum Bid Price Rule.
- Review the attached press release (Exhibit 99.1) for specific details on the compliance mechanism and any conditions imposed by NASDAQ.
- Confirm the status of the company's Registration Statements (File No. 333-262480 and 333-269306) now that this report has been incorporated by reference.